
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
U.S. officials are considering again whether to tighten restrictions on the use of a prescription drug that is highly effective against severe acne but can cause birth defects.